Skip to main content
Log in

The association of serum albumin with coronary slow flow

Zusammenhang zwischen Serum Albumin und langsamem Koronorarfluss

  • original article
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Summary

Background

A number of inflammatory markers such as high-sensitivity C-reactive protein (Hs-CRP), interleukin-6 (IL-6), and fibrinogen have been shown to be associated with coronary slow flow (CSF). Our aim was to investigate the relationship between albumin, a long-acting negative acute-phase protein, and CSF.

Methods

A total of 106 patients with angiographically proven slow coronary flow and 57 control subjects with normal coronary flow were included in the study. Serum levels of Hs-CRP and albumin were measured. CSF was defined by Thrombolysis In Myocardial Infarction (TIMI) frame count (TFC) method.

Results

Serum albumin (s-albumin) was significantly lower in the CSF group (3.79 ± 0.3 vs 4.17 ± 0.3, p < 0.001), whereas Hs-CRP level was significantly higher in the CSF group compared with the controls (1.22 ± 0.79 vs 0.76 ± 0.44, p < 0.001). S-albumin and Hs-CRP were correlated with the mean TFC in the whole study population (r= − 0.574, p < 0.001; r = 0.376, p < 0.001, respectively). Hs-CRP and low s-albumin were found to be significant predictors of CSF in the multivariate analysis. The comparison of receiver-operating characteristics curves for s-albumin and Hs-CRP demonstrated that s-albumin was the strongest predictor of CSF.

Conclusions

We found that s-albumin levels decreased and Hs-CRP levels increased in patients with CSF. S-albumin was also found to have superior predictive value than Hs-CRP for diagnosing CSF. S-albumin, an inexpensive and easily measurable laboratory variable, may be a useful predictor of CSF, especially when other reasons which alter its serum levels were excluded.

Zusammenfassung

Grundlagen

Von mehreren Entzündungsmarkern, wie hochsensitivem C-reaktiven Protein (hs-CRP), Interleukin-6 (IL-6) und Fibrinogen konnte gezeigt werden, dass sie mit langsamem koronarem Durchfluss („coronary slow flow“, CSF) vergesellschaftet sind. Ziel unserer Studie war es, zu prüfen, ob ein Zusammenhang zwischen Albumin, einem lang-wirksamen negativen Akutphasenprotein und CSF besteht.

Methodik

Insgesamt wurden 106 Patienten mit angiographisch nachgewiesenem CSF und 57 Kontrollen mit normalem Koronarfluss in die Studie aufgenommen. Die Serumkonzentrationen von hs-CRP und Albumin wurden gemessen. CSF wurde durch die TIMI (Thrombolysis In Myocardial Infarction) Frame Count (TFC) Methode erhoben.

Ergebnisse

Das Serum Albumin war in der Gruppe mit CSF im Vergleich zur Kontrolle signifikant erniedrigt (3,79 ± 0,3 vs 4,17 ± 0,3, p < 0,001) – die hs-CRP Konzentrationen dahingegen signifikant erhöht (1,22 ± 0,79 vs 0,76 ± 0,44, p < 0,001). Serum Albumin und hs-CRP waren in der Gesamtpopulation mit dem mittleren TFC korrelieret (r= − 0,574, p < 0,001; r = 0,376, p < 0,001, respektive). In der Multivarianzanalyse zeigte sich, dass hs-CRP und niedriges Serum Albumin signifikante Prädiktoren eines CSF sind. Der Vergleich der ROC Analysen für hs CRP und Serum Albumin ergab, dass das Serum Albumin der stärkste Prädiktor eines CSF war.

Schlussfolgerungen

Bei unseren Patienten mit CSF waren die Serum Albumin-Konzentrationen erniedrigt und die hs-CRP Werte erhöht. Das Serum Albumin war in unseren Händen der bessere Prädiktor als das hs-CRP für einen CSF. Serum Albumin ist ein billiger und leicht messbarer Laborparameter, der – nach Ausschluss anderer Albumin beeinflussender Faktoren - ein nützlicher Prädiktor für einen CSF sein kann.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Sezgin AT, Sıg˘ırcı A, Barutcu I, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis. 2003;14:155–61.

    Article  PubMed  Google Scholar 

  2. Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evidence for small-vessel coronary artery disease in patients with angina pectorisand patent large coronary arteries. Circulation. 1986;74:964–72.

    Article  CAS  PubMed  Google Scholar 

  3. Pekdemir H, Cin VG, Cicek D, et al. Slow coronary flow may be a sign of diffuse atherosclerosis. Contribution of FFR and IVUS. Acta Cardiol. 2004;59:127–33.

    Article  PubMed  Google Scholar 

  4. Cutri N, Zeitz C, Kucia AM, et al. ST/T wave changes during acute coronary syndrome presentation in patients with the coronary slow flow phenomenon. Int J Cardiol. 2011;146:457–8.

    Article  PubMed  Google Scholar 

  5. Horjeti B, Goda A. Acute ischemia manifestation in a patient with coronary slow flow phenomenon. J Electrocardiol. 2012;45:277–9.

    Article  PubMed  Google Scholar 

  6. Wozakowska-Kaplon B, Niedziela J, Krzyzak P, et al. Clinical manifestations of slow coronary flow from acute coronary syndrome to serious arrhythmias. Cardiol J. 2009;16:462–8.

    PubMed  Google Scholar 

  7. Saya S, Hennebry TA, Lozano P, et al. Coronary slow flow phenomenon and risk for sudden cardiac death due to ventricular arrhythmias: a case report and review of literature. Clin Cardiol. 2008;31:352–5.

    Article  PubMed  Google Scholar 

  8. Halliwell B. Albumin-an important extracellular antioxidant? Biochem Pharmacol. 1988;37:569–71.

    Article  CAS  PubMed  Google Scholar 

  9. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477–82.

    Article  CAS  PubMed  Google Scholar 

  10. Kuller LH, Eichner JE, Orchard TJ, et al. The relation between serum albumin levels and risk of coronary heart disease in the multiple risk factor intervention trial. Am J Epidemiol. 1991;134:1266–77.

    CAS  PubMed  Google Scholar 

  11. Gillum RF, Ingram DD, Makuc DM. Relation between serum albumin concentration and stroke incidence and death: the NHANES I epidemiologic follow-up study. Am J Epidemiol. 1994;140:876–88.

    CAS  PubMed  Google Scholar 

  12. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879–88.

    Article  CAS  PubMed  Google Scholar 

  13. Singh S, Kothari SS, Bahl VK. Coronary slow flow phenomenon: an angiographic curiosity. Indian Heart J. 2004;56:613–7.

    PubMed  Google Scholar 

  14. Gokce M, Kaplan S, Tekelioglu Y, Erdogan T, Kucukosmanoglu M. Platelet function disorder in patients with coronary slow flow. Clin Cardiol. 2005;28:145–8.

    Article  PubMed  Google Scholar 

  15. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.

    Article  CAS  PubMed  Google Scholar 

  16. Li JJ, Qin XW, Li ZC, et al. Increased plasma C-reactive protein and interleukin-6 concentrations in patients with slow coronary flow. Clin Chim Acta. 2007;385:43–7.

    Article  CAS  PubMed  Google Scholar 

  17. Madak N, Nazlı Y, Mergen H, et al. Acute phase reactants in patients with coronary slow flow phenomenon. Anadolu Kardiyol Derg. 2010;10:416–20.

    Article  PubMed  Google Scholar 

  18. Varol E, Gülcan M, Aylak F, et al. Increased neopterin levels and its association with angiographic variables in patients with slow coronary flow: an observational study. Anadolu Kardiyol Derg. 2011;11:692–7.

    PubMed  Google Scholar 

  19. Arı H, Arı S, Erdog˘an E, et al. The effects of endothelial dysfunction and inflammation on slow coronary flow. Turk Kardiyol Dern Ars. 2010;38:327–33.

    PubMed  Google Scholar 

  20. Turhan H, Saydam GS, Erbay AR, et al. Increased plasma soluble adhesion molecules; ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow. Int J Cardiol. 2006;108:224–30.

    Article  PubMed  Google Scholar 

  21. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci. 1982;389:39–48.

    Article  CAS  PubMed  Google Scholar 

  22. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141–212.

    Article  CAS  PubMed  Google Scholar 

  23. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal. 1999;13:273–9.

    Article  CAS  PubMed  Google Scholar 

  24. Nelson JJ, Liao D, Sharrett AR, et al. Serum albumin level as a predictor of incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2000;151:468–77.

    Article  CAS  PubMed  Google Scholar 

  25. Grimble R. Serum albumin and mortality [Letter]. The Lancet. 1990;335:350.

    Google Scholar 

  26. Doweiko JP, Bistrian BR. The effect of glycosylated albumin on platelet aggregation. J Parenter Enteral Nutr. 1994;18:516–20.

    Article  CAS  Google Scholar 

  27. Halliwell B. Albumin-an important extracellular antioxidant? Biochem Pharmacol. 1988;37:569–71.

    Article  CAS  PubMed  Google Scholar 

  28. Krijgsman B, Papadakis JA, Ganotakis ES, Mikhailidis DP, Hamilton G. The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. Int Angiol. 2002;21:44–52.

    CAS  PubMed  Google Scholar 

  29. Djoussé L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring study. Circulation. 2002;106:2919–24.

    Article  PubMed  Google Scholar 

  30. Koç F, Erdem S, Altunkas¸ F, et al. Ischemia-modified albumin and total antioxidant status in patients with slow coronary flow: a pilot observational study. Anadolu Kardiyol Derg. 2011;11:582–7.

    PubMed  Google Scholar 

  31. Selcuk H, Maden O, Selcuk MT, Celenk MK, Geyik B, Tufekcioglu O. Documentation of impaired coronary blood flow in chronic obstructive pulmonary disease patients. Circ J. 2010;74:346–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

All authors declared that there is no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mustafa Cetin MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cetin, M., Zencir, C., Tasolar, H. et al. The association of serum albumin with coronary slow flow. Wien Klin Wochenschr 126, 468–473 (2014). https://doi.org/10.1007/s00508-014-0559-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-014-0559-8

Keywords

Schlüsselwörter

Navigation